Jan 29 (Reuters) - India's Jubilant Pharmova JUBA.NS
reported a 51% jump in third-quarter profit on Friday, driven by
a strong demand for its drugs with radioactive ingredients, used
to treat cancer and other diseases.
Consolidated net profit rose to 1.01 billion rupees ($11.7
million) in the quarter ended Dec. 31, from 668 million rupees a
year ago.
Revenue rose 9% to 18.14 billion rupees, lifted by the
radiopharma segment's nearly 12% growth this quarter.
The segment accounted for nearly 46% of the total revenue.
The drugmaker, which manufactures and supplies
radiopharmaceuticals used to diagnose and treat cancer and other
diseases such as hyperthyroidism and lung diseases, has a
network of 52 radio-pharmacies in the United States.
Revenue from its contract manufacturing segment, the firm's
second-biggest segment that makes sterile injectables, rose
slightly, as did the generics business.
Jubilant Pharmova's shares jumped as much as 4.5% after the
results, but pared gains to last trade 1.5% higher.
($1 = 86.5940 Indian rupees)
(Reporting by Nandan Mandayam in Bengaluru; Editing by Eileen
Soreng)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))